Drug Trial Radar · NCT07574385
Sciatic Nerve Block With ALX006 in Subjects Undergoing Bunionectomy
Last checked: Nov 20, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Mar 10, 2026
Primary completion
Aug 2026
Study completion Aug 2026
Sponsor
- Lead sponsor
- Rebel Medicine IncIndustry
- Sponsor type
- Industry
- First posted
- May 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, randomized, double-blind, active-controlled, dose-escalation study evaluating the safety, pharmacokinetics, efficacy, and pharmacodynamics of ALX006, an extended-release bupivacaine formulation, administered as a single-dose sciatic nerve block in the popliteal fossa in adult subjects undergoing primary unilateral bunionectomy. Approximately 60 subjects will be enrolled across 3 sequential dose cohorts (100 mg, 150 mg, 200 mg ALX006), with each cohort comparing ALX006 against MARCAINE 0.25% (bupivacaine HCl 50 mg) as the active comparator at a 3:1 randomization ratio. Dose escalation between cohorts is governed by an Independent Data Monitoring Committee.
Conditions
- Hallux Valgus
- Bunionectomy
Interventions
ALX006 (bupivacaine extended-release injection)Drug
ALX006 (50 mg/mL bupivacaine free base)
Bupivacaine Hcl 0.25% InjDrug
Bupivacaine HCl 0.25% plain (2.5 mg/mL)
Sciatic Nerve BlockProcedure
Sciatic nerve block in the popliteal fossa
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: From start of nerve block procedure through 360 Hour Visit (Day 15)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CenExel Salt Lake City
Millcreek, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.